Clin Lipidology. 2010;5(3):309-323. The usual starting dose of pitavastatin is 1 mg once daily. The dose should be adjusted at intervals of at least 4 weeks according to LDL-C levels, the goal of ...

H ealth outcomes in humans often show daily variations. For instance, morning vaccinations may trigger a more effective ...

For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million ...

Alzheimer's disease, a devastating neurodegenerative condition that affects millions of people worldwide, may have found a ...

The researchers said: 'We found that lipid-lowering drugs, particularly statins, were associated with decreased risk of 21 ...

It is estimated that about 50% of atherosclerotic cardiovascular disease is not driven by LDL-cholesterol – the target of most lipid-lowering drugs, including statins and PCSK9 inhibitors like ...

AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.

Obicetrapib was tested as a monotherapy and in combination with lipid-lowering medications like statins. The topline results from the pivotal BROOKLYN trial were announced in July 2024.

Heart disease is the No. 1 killer of Americans. However, having high cholesterol levels doesn’t always lead to heart disease, a South Florida cardiac specialist has discovered. Dr. Jonathan ...

DelveInsight’s, “Peripheral Arterial Disease Pipeline Insight 2024” report provides comprehensive insights about 18+ ...

AMSTERDAM, Oct. 07, 2024 (GLOBE NEWSWIRE) -- VIVUS BV, a subsidiary of VIVUS LLC, today announced the availability of QSIVA ® (phentermine and topiramate modified-release) in Sweden, Denmark, Finland, ...